Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome (Q37179405)

18 August 2017

1 reference

title

Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome (English)

1 reference

18 August 2017

1 reference

Harry H Yoon

1 reference

18 August 2017

Arlene A Forastiere

series ordinal

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

18 August 2017

page(s)

413-425

1 reference

Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Predictive and prognostic molecular markers in outcome of esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Clinical trial designs for predictive marker validation in cancer treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Tumor marker expression is predictive of survival in patients with esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Targeted therapy trials: approval strategies, target validation, or helping patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Cancer. p53, guardian of the genome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Focus on Barrett's esophagus and esophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Loss of Bcl-2 expression in Barrett’s dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Promoter methylation and response to chemotherapy and radiation in esophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.413

21 January 2018

Identifiers

DOI

10.2217/14796694.4.3.413

1 reference

18 August 2017

1 reference